Clinical Trial Update: A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension [Phase 3]

View source ↗

Summary

Phase 3b study evaluating 24-hour intraocular pressure lowering effect of Bimatoprost SR in open-angle glaucoma or ocular hypertension has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Bimatoprost SR (bimatoprost)

Snippet

Sponsor: AbbVie | Conditions: Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2023-06-08